Recurrent Stroke Prevention Strategies in Patients Receiving Acute Stroke Reperfusion Therapies (CoPrime Study Survey)
Strategien zur Prävention rezidivierender Schlaganfälle bei Patient:innen mit akuter Reperfusionsbehandlung: CoPrime-Studie (Survey)
Cerebrovascular Diseases Extra · 30.05.2025 · 15 (1) · 162-172
DOI: 10.1159/000546654 ↗Auf einen Blick
Die Umfrage unter 278 Kliniker:innen aus 26 Ländern zeigt heterogene Praktiken zur antithrombotischen Sekundärprävention nach Reperfusion. Mehr als drei Viertel waren für eine Randomisierung in einer Studie offen.
Fragestellung
Wie handhaben und bewerten Ärzt:innen die duale Thrombozytenaggregationshemmung nach Reperfusionsbehandlung bei nicht kardioembolischem ischämischem Schlaganfall?
Methode
Multinationale webbasierte Querschnittsumfrage mit 278 Kliniker:innen; Befragung zu Praxis, sechs Fallvignetten und Randomisierungsbereitschaft; multinomiale logistische Regression.
Ergebnisse
278 Kliniker:innen aus 26 Ländern nahmen teil. Bei kleinem Infarkt nach i.v. Thrombolyse und EVT bevorzugten 194/278 Aspirin, 49/278 eine duale Therapie. 61/278 nannten frühe Initiation sofort nach EVT, 103/278 nach 24 h.
Schlussfolgerung der Autor:innen
Das antithrombotische Management zur Sekundärprävention ist nach Reperfusion variabel. Mehr als drei Viertel der Teilnehmenden waren bereit, eine Studie zur Prävention rezidivierender Schlaganfälle zu randomisieren.
Kernaussagen
- Aspirin war die häufigste Wahl nach Reperfusion.
- Die Timing- und Loading-Strategien variierten deutlich.
- Mehr als drei Viertel waren für Randomisierung offen.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift Cerebrovascular Diseases Extra, online erschienen am 30.05.2025. Verfasst von Rezan Ashayeri Ahmadabad und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada, rezan@ualberta.ca. Hauptthemen laut MEDLINE: Endovascular Procedures, Ischemic Stroke, Platelet Aggregation Inhibitors, Practice Patterns, Physicians'. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Introduction
Patients who have undergone reperfusion treatments, like all ischemic stroke patients, are at risk of recurrent ischemic strokes in the first 90 days. Current guidelines recommend single antiplatelet therapy for secondary prevention at variable time points after the procedure. This study assessed the practices and perspectives of healthcare professionals on the use of dual antiplatelet therapy in patients with non-cardioembolic ischemic stroke who have undergone reperfusion therapy.
Methods
We conducted a multinational cross-sectional web-based survey using Qualtrics involving neurologists and non-neurologist stroke physicians (including neurosurgeons, interventional neuroradiologists, and internal medicine physicians). Participants were asked about their current practices and presented with six structured case scenarios to determine their treatment preferences. In the case scenarios, we assessed their willingness to randomize to a clinical trial comparing single versus dual antiplatelets. Multinomial logistic regression analysis was performed to assess the relationship between demographic characteristics and willingness to randomize.
Results
A total of 278 clinicians from 26 countries participated in the survey. The most common continent of practice was Asia (155/278; 55.9%). The most common area of practice was neurology (220/278; 79.1%), with most participants having 5–15 years of experience (115/278; 41.5%) and working in comprehensive stroke centers (205/278; 73.9%). Antiplatelet Choice: For a small infarct post-intravenous thrombolysis and endovascular thrombectomy (EVT), 194/278 (69.8%) preferred aspirin, and 49/278 (17.6%) chose a dual antiplatelet strategy with aspirin and clopidogrel. Loading of Antiplatelet: A total of 121/278 (43.5%) indicated they would not administer a loading dose in cases even with small final infarctions. Timing of Antiplatelet Initiation: Preferences varied; 61/278 (21.7%) considered early initiation immediately post-EVT, and 103/278 (37.2%) considered 24 h post-EVT. Willingness to Randomize: A total of 16/278 (77.7%) were willing or would consider randomizing in a clinical trial with dual antiplatelet. On regression analyses, the willingness to randomize was influenced by years of practice and the local volume of reperfusion therapy.
Conclusion
Antiplatelet management for secondary stroke prevention in patients with non-cardioembolic ischemic stroke following reperfusion therapy is variable. However, more than three-fourths of participants were willing to consider randomization to a clinical trial exploring the prevention of recurrent stroke after reperfusion therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada, rezan@ualberta.ca.
- Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
- Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, India.
- Division of Clinical Science, Health Sciences North, Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
- Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Zitieren
APA
Ashayeri Ahmadabad, R., Almekhlafi, M., Sylaja, P. N., Deshmukh, A., Dawson, J., Pikula, A., Hussain, M. S., Zhang, Y., Asdaghi, N., Sohn, S. I., Wasay, M., Shuaib, A., Buck, B., & Kate, M. P. (2025). Recurrent Stroke Prevention Strategies in Patients Receiving Acute Stroke Reperfusion Therapies (CoPrime Study Survey). Cerebrovascular Diseases Extra, 15(1), 162-172. https://doi.org/10.1159/000546654
Vancouver
Ashayeri Ahmadabad R, Almekhlafi M, Sylaja PN, Deshmukh A, Dawson J, Pikula A, et al. Recurrent Stroke Prevention Strategies in Patients Receiving Acute Stroke Reperfusion Therapies (CoPrime Study Survey). Cerebrovascular Diseases Extra. 2025;15(1):162-172. doi:10.1159/000546654
BibTeX
@article{AshayeriAhmadabad2025,
author = {Ashayeri Ahmadabad, Rezan and Almekhlafi, Mohammed and Sylaja, P N and Deshmukh, Aviraj and Dawson, Jesse and Pikula, Aleksandra and Hussain, Muhammad Shazam and Zhang, Yiran and Asdaghi, Negar and Sohn, Sung-Ii and Wasay, Mohammad and Shuaib, Ashfaq and Buck, Brian and Kate, Mahesh Pundlik},
title = {Recurrent Stroke Prevention Strategies in Patients Receiving Acute Stroke Reperfusion Therapies (CoPrime Study Survey)},
journal = {Cerebrovascular Diseases Extra},
year = {2025},
volume = {15},
number = {1},
pages = {162--172},
doi = {10.1159/000546654}
}
EUVIMED